VanEck Associates
CRSP icon

VanEck Associates’s CRISPR Therapeutics CRSP Stock Holding History

VanEck Associates’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-85,294
Closed -$4.06M – 1362
2026
Q1 		$4.06M Sell
85,294
-537
-0.6% -$28.3K ﹤0.01% 866
2025
Q4 		$4.5M Buy
85,831
+2,187
+3% +$131K ﹤0.01% 820
2025
Q3 		$5.42M Buy
83,644
+634
+0.8% +$36.4K 0.01% 736
2025
Q2 		$4.04M Hold
83,010
– – ﹤0.01% 800
2025
Q1 		$2.83M Hold
83,010
– – ﹤0.01% 899
2024
Q4 		$3.27M Buy
83,010
+81,464
+5,269% +$3.85M ﹤0.01% 839
2024
Q3 		$71K Sell
1,546
-78,228
-98% -$3.97M ﹤0.01% 1266
2024
Q2 		$4.31M Buy
79,774
+7,830
+11% +$453K 0.01% 631
2024
Q1 		$4.9M Buy
71,944
+4,103
+6% +$294K 0.01% 588
2023
Q4 		$4.25M Sell
67,841
-4,989
-7% -$276K 0.01% 587
2023
Q3 		$3.31M Sell
72,830
-3,933
-5% -$203K 0.01% 612
2023
Q2 		$4.31M Sell
76,763
-5,863
-7% -$333K 0.01% 545
2023
Q1 		$3.74M Sell
82,626
-10,715
-11% -$520K 0.01% 550
2022
Q4 		$3.79M Buy
93,341
+14,084
+18% +$747K 0.01% 533
2022
Q3 		$5.18M Sell
79,257
-47,002
-37% -$3.41M 0.02% 430
2022
Q2 		$7.67M Buy
126,259
+12,198
+11% +$717K 0.02% 374
2022
Q1 		$7.16M Buy
114,061
+10,015
+10% +$629K 0.01% 431
2021
Q4 		$7.88M Buy
104,046
+7,694
+8% +$672K 0.02% 418
2021
Q3 		$10.8M Sell
96,352
-7,807
-7% -$980K 0.03% 337
2021
Q2 		$16.9M Sell
104,159
-14,922
-13% -$1.81M 0.04% 272
2021
Q1 		$14.5M Buy
+119,081
New +$18M 0.04% 278

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VanEck Associates's CRSP Position: Q2 2026 in Review

VanEck Associates sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 85,294 shares — an estimated $4.06M sold.

VanEck Associates first reported a position in CRSP in Q1 2021 and held it in 21 quarters. The position peaked at $16.9M in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • VanEck Associates reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • VanEck Associates sold 85,294 CRISPR Therapeutics shares in Q2 2026, an estimated $4.06M.
  • VanEck Associates first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 21 quarters.
  • VanEck Associates's CRISPR Therapeutics position peaked at $16.9M in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.